Equasens: Q3 2023 revenue
November 09 2023 - 12:00PM
Equasens: Q3 2023 revenue
Villers-lès-Nancy, 9 November 2023 - 6:00 p.m.
(CET)
PRESS RELEASE
Q3 2023 revenue
-
Q3 2023 revenue: stable year-on-year at
€50.1m
-
Growth impacted by:
-
The completed deployment of solutions under the Ségur French
Digital Healthcare investment programme:
-
Adverse market conditions affecting Pharmacy sector.
In €m |
2022 |
2023 |
Change2023 / 2022 |
Q1 |
49.4 |
56.3 |
+14% (*) |
Q2 |
54.2 |
56.3 |
4 % |
Q3 (unaudited) |
50.1 |
50.1 |
0 % |
9 month YTD |
153.7 |
162.7 |
6 % |
(*) Strong growth in Q1 reflecting a favourable
comparison base (restructuring of the electronic labelling
activity).
____________
Q3 2023 business
highlights:
- The PHARMAGEST
Division reported revenue of €36.8m, marginally down on Q3
2022 (-1%). For the first 9 months, revenue rose 6% to €120.5m.
- The hardware
configuration business was down in relation to Q3 2022,
reflecting notably completion of the technical compliance campaign
for the installed base combined with the rollout of Ségur
functionalities.
- The economic
environment impacted by inflation and rising operating costs,
combined with a financial context unfavourable for investment, also
adversely impacted equipment purchases by pharmacies, including for
electronic labels.
- Driven by the
success of new offerings, and in particular messaging, mobility and
back-up solutions, sales of licenses and services remain
buoyant.
- Recurring revenue
continue to show strong growth.
- This Division
accounted for 74 % of Equasens Group's total revenue.
- The AXIGATE LINK
Division had revenues of €7.4m, up 6% on Q3 2022. Revenue
for the first 9 months rose 6% to €22.3m.
- The Division is
continuing to grow in its historical market segments of nursing
homes and hospital-at-home care.
- The TITANLINK
solution continues to display strong growth, particularly in
Belgium, as new functionalities, such as CARELIB, are being
integrated into the software.
- This Division
accounted for 14 % of Equasens Group's total revenue.
- The E-CONNECT
Division had revenue of €3.6m, with strong growth of 23%
compared with Q3 2022. Revenue for the first nine months rose 13%
to €11.7m.
- Once again, the
Division registered a very good performance for the quarter:
Mobility solutions have been a genuine success, made possible by
the Division's ability to meet the challenges of production
capacity and component sourcing.
- This Division
accounted for 7 % of Equasens Group's total revenue.
- The MEDICAL SOLUTIONS
Division had revenue of €1.8m, down 24% on Q3 2022. For
the full first nine months, total revenue remained stable
year-on-year, at €6.7m.
- This decline in
revenue reflects the end of Medistory 4 license sales in H1 linked
to the Ségur rollout initiated in Q3 2022.
- Today, the Division
is offering a new subscription-based version of its Médistory
software representing a source of recurring revenue.
- This Division
accounted for 4 % of Equasens Group's total revenue.
- The FINTECH
Division reported sales of €0.4m for Q3 2022 and €1.5m for
the first 9 months, unchanged in relation to the same periods in
2022.
- The continuing rise
in refinancing rates continues to penalise the financing brokerage
activity.
- This Division
accounted for 1 % of Equasens Group's total revenue.
2023 outlook
- Excluding the
comparison base effect from the end of the Ségur deployment in 2022
and its exceptional contribution to revenue, growth momentum of the
PHARMAGEST Division's remains solid.
- The AXIGATE LINK
and e-CONNECT Divisions are also confident that their growth levels
will remain strong for the remainder of the year.
- The MEDICAL
SOLUTIONS Division is currently restructuring its offering and
organization in order to enhance its performance.
- Based on the
positive results of a major business development campaign, the
FINTECH Division is confident about its outlook for year-end.
- The Group will
continue to be on the lookout for external growth opportunities in
France and Europe.
Financial
calendar:
- Q4 2023 revenue: 6 February
2024
About Equasens
Group:
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group
today brings together healthcare professionals within a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020
- CAC® SMALL and CAC® All-TradableIncluded in the Euronext Tech
Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR 0012882389 – Ticker
Code: EQS
Get all the news about the Equasens
Group www.equasens.com and
on LinkedIn
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Frédérique SCHMIDTTel: +33 (0)3 83 15 90 67 -
frederique.schmidt@equasens.com
Media Relations:
FIN’EXTENSO - Isabelle Aprile
Tel.: +33 (0)6 17
38 61 78 – i.aprile@finextenso.fr
- EQUASENS_PressRelease_20231109_Q3-2023-revenue-EN
Equasens (EU:EQS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Equasens (EU:EQS)
Historical Stock Chart
From Sep 2023 to Sep 2024